Outline of Consolidated Financial Results for the 3rd Quarter Ended December 31, 2012





Operating Results

	3QFY2011		3QFY	2012	YoY Change		
	Results	Ratio	Results	Ratio	Amt	%	
Net sales	50,423	100.0%	51,514	100.0%	1,090	2.2%	
Operating income	5,200	10.3%	5,361	10.4%	161	3.1%	
Ordinary income	5,336	10.6%	5,698	11.1%	361	6.8%	
Net income	3,081	6.1%	3,557	6.9%	476	15.5%	



Segmental Review – Pharmaceuticals –

(Million yen)

	3QFY	/2011	3QFY	Y2012	YoY C	hange
	Results	Ratio	Results	Ratio	Amt	%
Ethical drugs	40,596	97.9%	41,945	98.3%	1,348	3.3%
Revenues from the licensing of industrial property rights	92	0.2%	94	0.2%	2	2.5%
Prulifloxacin	642	1.6%	507	1.2%	△ 135	∆21.1%
Contract manufacturing business	141	0.3%	121	0.3%	△ 19	∆13.9%
Net sales	41,473	100.0%	42,668	100.0%	1,195	2.9%

etc.

Increase in sales:


- Vidaza (+2,012million yen, +61.7%) (Remedy for myelodysplastic sydromes)
- Lunabell (+903million yen, +31.8%) (Remedy for dysmenorrhea)
- Adcirca (+610million yen, +74.9%) (Pulmonary arterial hypertension treatment agent)

Decrease in sales:

- Hypen (\triangle 805million yen, \triangle 23.4%) (Non-steroidal analgesic and anti-inflammatory agent)
- Eviprostat (Δ606million yen, Δ13.2%) (Remedy for benign prostatic hyperplasia)

etc.

Segmental Review – Pharmaceuticals –







Segmental Review – Functional Food –

	3QFY2011		3QFY	′2012	YoY Change		
	Results	Ratio	Results	Ratio	Amt	%	
Health food ingredients	660	7.4%	592	6.7%	∆ 67	∆10.3%	
Preservatives	1,216	13.6%	1,305	14.8%	88	7.3%	
Protein preparations	4,555	50.9%	4,500	50.9%	∆ 5 4	∆1.2%	
Nutritional ingredients	1,317	14.7%	1,335	15.1%	17	1.3%	
Others	1,202	13.4%	1,113	12.5%	∆ 89	∆7.4%	
Net sales	8,950	100.0%	8,845	100.0%	∆ 105	∆1.2%	

Segmental Review – Functional Food –



Net Sales





	3QFY	2011	3QFY	2012	YoY Change	
	Results	ResultsRatioResultsRatio		Ratio	Amt	%
Revenue						
Net sales	50,423	100.0%	51,514	100.0%	1,090	2.2%
Pharmaceuticals	41,473	82.2%	42,668	82.8%	1,195	2.9%
Functinal Food	8,950	17.8%	8,845	17.2%	∆ 105	∆ 1.2%
Operating expenses	45,223	89.7%	46,152	89.6%	928	2.1%
Cost of sales	24,152	47.9%	25,471	49.4%	1,318	
SG&A expenses	14,215	28.2%	14,270	27.8%	54	
R&D expenses	6,855	13.6%	6,411	12.4%	△ 444	
Operating income	5,200	10.3%	5,361	10.4%	161	3.1%




	3QFY	2011	3QFY	2012	YoY Change		
	Results	Ratio	Results	Ratio	Amt	%	
Operating income	5,200	10.3%	5,361	10.4%	161	3.1%	
Non-operating income	624	1.2%	714	1.4%	90	14.4%	
Non-operating expenses	488	1.0%	378	0.7%	∆ 110	∆22.5%	
Ordinary income	5,336	10.6%	5,698	11.1%	361	6.8%	
Income taxes, etc	2,239	4.5%	2,127	4.2%	∆ 111	∆5.0%	
Net income	3,081	6.1%	3,557	6.9%	476	15.5%	



	FY2011	FY2012	YoY Change		FY2011	FY2012	YoY Change
	4Q	3Q	Amt		4Q	3Q	Amt
Assets	106,304	107,687	1,383	Liabilities	21,738	21,032	∆ 705
(Current assets)	66,333	68,191	1,858	(Current liabilities)	13,961	13,231	∆ 729
(Fixed assets)	39,971	39,496	∆ 475	(Long-term liabilities)	7,776	7,801	24
				Net assets	84,566	86,655	2,088
Total Assets	106,304	107,687	1,383	Total liabilities and net assets	106,304	107,687	1,383

Business Forecast for the Year Ending March 31,2013



🕥 NIPPON SHINYAKU CO., LTD.

11

Status of Development Pipeline





R&D Compounds (Domestic)

Code No. (Generic name) <origin></origin>	Application type	Indications	Stage	2010	2011	2012	2013
NS-11 (acamprosatecalcium) <in-licence></in-licence>	NME	support maintenance of abstinence from alcohol in patients with alcohol dependence	Pre- registration	РШ	Fil	Appro DA Plann ing •	
NS-315 (tramadol hydrochloride) <in-licence></in-licence>	new indication	chronic non-cancer pain	Pre- registration	РШ		NDA Filing	Approval Planned
LY450190 (tadalafil)	new	urinary disorder caused by benign prostatic	РШ	Eli LIIIy Japan k.k.			
<in-licence></in-licence>	indication	hyperplasia	ГШ	РШ			
NS-24 (tramadol hydrochloride) <in-licence></in-licence>	new formulation	cancer pain chronic non-cancer pain	РШ	PI	PII		
ACT-064992 (macitentan) <in-licence></in-licence>	NME	pulmonary arterial hypertension	РШ			РШ	
GA101 (obinutuzumab) <in-licence></in-licence>	NME	indolent non-Hodgkin's lymphoma aggressive non-Hodgkin's lymphoma	ΡШ		PII -		



R&D Compounds (Domestic)

Code No. (Generic name) <origin></origin>	Application type	Indications	Stage	2010	2011	2012	2013
NS-304		pulmonary arterial hypertension	ΡI	ΡI			
(selexipag) <in-house></in-house>	NME	chronic thromboembolic pulmonary hypertension	ΡI	PI			PII Planned
NS-141 <in-house></in-house>	NME	pruritus associated with atopic dermatitis	ΡI	PI 🗕			



R&D Compounds(Overseas)

((Code No. Generic name) <origin></origin>	Application type	Indications	Stage	2010	2011	2012	2013
	prulifloxacin <in-house></in-house>		hastorial infactions	Korea Approval	Yuhan			
				China Preparation for PII	Lee's Pharma		PII Planned	
	NS-304 (selexipag)	NME	pulmonary arterial	US/EU PⅢ	Actelion社			
	<in-house></in-house>		hypertension	РШ	РШ			_
	NS-187 (bafetinib) NME <in-house></in-house>		B-cell chronic lymphocytic leukemia	US P II	CytRx社 P II			
			chronic myelogenous leukemia	US/EU Preparation P II				
	NS-018 <in-house></in-house>	NME	myelofibrosis	US PI/PI		PI/I		



Safe Harbor Statement

- Materials and information provided during this presentation may contain so-called "forward-looking statements." These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could causeactual outcomes and results to differ materially from these statements.
- Risks and uncertainties include general industry and market conditions, and general domestic and international economic conditions such as interest rate and currency exchange fluctuations. Risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, technological advances and patents attained by competitors; challenges inherent in new product development, including completion or failure of clinical trials; claims and concerns about product safety and efficacy; regulatory agency's examination, obtaining regulatory approvals; domestic and foreign social security reforms; trends toward healthcare cost containment; and governmental laws and regulations affecting domestic and foreign operations.
- Also, for products that are approved, there are manufacturing and marketing risks and uncertainties, which include, but are not limited to, inability to build production capacity to meet demand, unavailability of raw materials, and competition with others.
- The Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.
- This English presentation was translated from the original Japanese version.
 In the event of any inconsistency between the statements in the two versions, the statements in the Japanese version shall prevail.